Morepen Laboratories Ltd
MOREPENLABMorepen Laboratories Ltd
MOREPENLAB
Price Chart
Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 35.82 | 5.55 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 51.53 | 6.56 | 0.52% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Morepen Laboratories Limited is a pharmaceutical company. The Company operates through four segments; they are Active Pharmaceutical Ingredients (API), Domestic Formulations, Diagnostics and Over the Counter (OTC).
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Mankind Pharma Ltd
Dr Reddy's Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 486.29 | 599.19 | 610.23 | 772.21 | 862.55 | 1,200.13 | 1,557.14 | 1,423.66 | 1,704.40 | 1,777.29 | ||||||||||
Raw Materials | 303.71 | 381.14 | 365.10 | 516.38 | 567.65 | 822.13 | 1,059.36 | 939.26 | 1,060.31 | 1,565.94 | ||||||||||
| Power & Fuel Cost | 7.64 | 9.84 | 11.08 | 13.18 | 12.56 | 13.00 | 18.93 | 23.78 | 34.09 | |||||||||||
| Employee Cost | 58.29 | 69.69 | 76.53 | 95.36 | 109.91 | 135.59 | 164.25 | 154.68 | 181.47 | |||||||||||
| Selling & Administrative Expenses | 43.72 | 53.46 | 61.08 | 73.30 | 81.73 | 92.40 | 102.60 | 150.78 | 182.36 | |||||||||||
| Operating & Other expenses | 14.56 | 19.96 | 27.99 | 2.80 | 12.70 | 6.43 | 65.01 | 69.49 | 73.57 | |||||||||||
EBITDA | 58.37 | 65.10 | 68.45 | 71.19 | 78.00 | 130.58 | 146.99 | 85.67 | 172.60 | 211.35 | ||||||||||
| Depreciation/Amortization | 35.20 | 33.90 | 34.32 | 39.90 | 36.91 | 30.28 | 27.64 | 27.93 | 33.47 | 25.66 | ||||||||||
| PBIT | 23.17 | 31.20 | 34.13 | 31.29 | 41.09 | 100.30 | 119.35 | 57.74 | 139.13 | 185.69 | ||||||||||
| Interest & Other Items | 10.50 | 7.56 | 4.36 | 2.11 | 1.98 | 1.79 | -7.37 | 1.98 | 3.71 | 5.30 | ||||||||||
| PBT | 12.67 | 23.64 | 29.77 | 29.18 | 39.11 | 98.51 | 126.72 | 55.76 | 135.42 | 180.39 | ||||||||||
| Taxes & Other Items | -0.13 | 0.00 | 0.18 | 0.33 | 5.53 | 1.42 | 25.02 | 17.08 | 39.25 | 49.12 | ||||||||||
| Net Income | 12.80 | 23.64 | 29.59 | 28.85 | 33.58 | 97.09 | 101.70 | 38.68 | 96.17 | 131.27 | ||||||||||
| EPS | 0.28 | 0.53 | 0.66 | 0.64 | 0.75 | 2.16 | 2.19 | 0.78 | 1.88 | 2.57 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Morepen Laboratories Ltd | 48.89 | 5.55 | — |
| Sun Pharmaceutical Industries Ltd | 45.35 | 6.47 | 0.75% |
| Cipla Ltd | 28.51 | 4.38 | 0.89% |
| Torrent Pharmaceuticals Ltd | 68.45 | 16.54 | 0.84% |
Price Comparison
Compare MOREPENLAB with any stock or ETFShareholdings
Promoter Holdings Trend
Decreased Total Promoter Holding
In last 6 months, promoter holding in the company has decreased by 2.57%
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Increased Total Retail Holding
In last 3 months, retail holding in the company has increased by 1.82%
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Mar 2024
Jun 2024
Aug 2024
Sep 2024
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 1 Mutual Funds holding Morepen Laboratories Ltd
| Funds (Top 1) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
Bandhan BSE Healthcare Index Fund Direct Plan-Growth Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.0008% | Percentage of the fund’s portfolio invested in the stock 0.21% | Change in the portfolio weight of the stock over the last 3 months 0.21% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 56/102 (-3) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividends
MOREPENLAB has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
Hmm, looks like data is unavailable here. Please come back after some timeNet profit of Morepen Laboratories rose 63.92% to Rs 34.85 crore in the quarter ended September 2024 as against Rs 21.26 crore during the previous quarter ended September 2023. Sales rose 3.78% to Rs 437.73 crore in the quarter ended September 2024 as against Rs 421.77 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales437.73421.77 4 OPM %10.077.96 - PBDT47.8836.37 32 PBT46.0228.68 60 NP34.8521.26 64 Powered by Capital Market - Live
Morepen Laboratories will hold a meeting of the Board of Directors of the Company on 11 November 2024Powered by Capital Market - Live
Morepen Laboratories announced that the Annual General Meeting (AGM) of the company will be held on 28 September 2024.Powered by Capital Market - Live
Morepen Laboratories has appointed Sharad Jain (DIN: 06423452) as an Independent Director, for a term of 5 consecutive years, effective from 27 August 2024. Powered by Capital Market - Live
Net revenue increased by 14% year-over-year (YoY) to Rs 458.64 crore during the period under review. The company holds a strong position in the Blood Glucometers and Blood Pressure (BP) Monitors markets. In Q1 FY25, the medical devices business recorded revenue of Rs 138 crore, marking a 20% growth year-on-year. Pharma segment Q1 FY25 revenue at Rs 320 crore registered a growth of 11% year-on-year, and it represents 70% of consolidated Q1 FY25 quarterly revenues. EBIDTA improved by 93% to Rs 55.05 crore in Q1 FY25 from Rs 28.51 crore in Q1 FY24. Profit before tax in Q1 FY25 stood at Rs 48.17 crore, up by 135% from Rs 20.51 crore in Q1 FY24. Morepen Laboratories said that the company's Blood Glucometer meter capacity would be doubled to 5.0 million meter pa from the current 2.5 million meter, while strip manufacturing capacity will increase from 500 million strips to 700 million strips per annum within the next 18 months. The company has successfully completed the subscription of a QIP for Rs. 200 crores on 5 August 2024. The issue was oversubscribed by 1.68 times, demonstrating strong confidence from institutional investors. Marquee global investors like Bank of America Securities Europe (BOFA), Samsung India, Citigroup, Societe Generale, Nomura, BNP Paribas, Morgan Stanley and Eminence are some of the select names that have partnered with Morepen, paving the way for a promising future. Sushil Suri, chairman and managing director of Morepen Laboratories, commented on the QIP, stating, 'This strategic fundraise marks a pivotal point in the company's growth journey. With the influx of this new capital, we will accelerate our capacity expansion plans and broaden our market reach.' Morepen Laboratories is an established player in domestic and international Active Pharmaceutical Ingredients ('API') markets. It is also planning to enter the anti-cancer segment by considering development of various potential candidates from list of top 100 synthetic molecules. The company also engaged in home diagnostics products, formulations and grooming products under the brand name GUBB. Powered by Capital Market - Live
Net profit of Morepen Laboratories rose 147.23% to Rs 36.17 crore in the quarter ended June 2024 as against Rs 14.63 crore during the previous quarter ended June 2023. Sales rose 13.51% to Rs 455.22 crore in the quarter ended June 2024 as against Rs 401.04 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales455.22401.04 14 OPM %11.346.51 - PBDT53.8928.23 91 PBT48.1720.51 135 NP36.1714.63 147 Powered by Capital Market - Live
Morepen Laboratories will hold a meeting of the Board of Directors of the Company on 12 August 2024.Powered by Capital Market - Live
Morepen Laboratories announced the successful subscription of a Qualified Institutional Placement (QIP) for Rs. 200 crore. The issue was subscribed 1.68 times with bids of Rs. 335 crore against the Rs. 200 crore offering, demonstrating strong confidence reposed by institutional investors. Marquee global investors like Bank of America Securities Europe (BOFA), Samsung India, Citigroup, Societe Generale, Nomura, BNP Paribas, Morgan Stanley and Eminence are some of the select names that have partnered with Morepen, paving the way for a promising future. Motilal Oswal Investment Advisors was the book running lead manager (BRLM) for the issue. Powered by Capital Market - Live
Morepen Laboratories Launches Rs 250-Crore QIP
Muthoot Finance, Morepen Laboratories, and Force Motors: What the Charts Say
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 17.16%, vs industry avg of 9.03%
Increasing Market Share
Over the last 5 years, market share increased from 0.35% to 0.45%
Higher than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 27.23%, vs industry avg of 15.27%